Abstract
Background: Cervical caner is the leading cause of female cancer death worldwide. The squamous cell carcinoma (SCC) antigen was isolated first from uterine cervical SCC tissue in 1977. SCC antigen is a serologic tumor marker for patients with squamous cell carcinoma of the cervix. Serum concentrations of this marker correlate well with stage of disease, the presence or absence of risk factors, the effect of treatment, and the course of the disease. Moreover, the measurement of posttreatment SCC antigen levels is useful for monitoring the response to therapy and for predicting tumor recurrence and metastasis. In advance or recurrence cervical cancer, radiation with chemotherapy including 5-FU is used clinically. However, the morbidity is relative high. Gene therapy combined with radiation represents a new approach to cervical cancer treatment. In the present study, we investigated whether adenovirally directed, SCC antigen promoter with cytosine deaminase (CD)/5-fluorocytosine (5-FC) gene therapy could induce cell toxicity and radiosensitization through the intracellular production of 5-fluorouracil (5-FU) in uterine cervical cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
